1 / 7

EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study

raimundo
Download Presentation

EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Purpose To evaluate the effects of eplerenone (a selective aldosterone blocker) on morbidity and mortality among patients with acute myocardial infarction (MI) complicated by left ventricular dysfunction and heart failure Reference Pitt B, Remme W, Zannad F et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:130921.

    2. EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study - TRIAL DESIGN - Design Multicenter, multinational, randomized, double-blind, placebo-controlled Patients 6632 patients 314 days after acute MI, who had left ventricular ejection fraction <40% and were receiving optimal treatment, which could include ACE inhibitors, angiotensin receptor blockers, diuretics (other than K+-sparing diuretics) and beta-blockers Follow up and primary endpoints Primary endpoints: all-cause mortality; death from cardiovascular cause or first hospitalization for cardiovascular event. Mean 16 months follow up. Treatment Placebo or eplerenone titrated to target dose 50 mg daily

    3. EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study - TRIAL DESIGN continued -

    4. EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study - RESULTS - Both primary endpoints significantly reduced in eplerenone group compared with placebo: all-cause mortality: 14.4 vs. 16.7% (RR 0.85, P=0.008) death or hospitalization due to cardiovascular event: 26.7 vs. 30.0% (RR 0.87, P=0.002) Significantly fewer hospitalizations for cardiovascular events in eplerenone group, attributable to significant reduction in hospitalizations for heart failure Incidence of gynecomastia in the two groups was similar Incidence of serious hyperkalemia significantly higher in eplerenone group; serious hypokalemia significantly lower Drug well tolerated as defined by withdrawal rate from trial: only marginally higher with eplerenone

    5. EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study - RESULTS continued -

    6. EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study - RESULTS continued -

    7. EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study - RESULTS continued -

    8. EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study - SUMMARY - In patients with acute myocardial infarction (MI) complicated by left ventricular dysfunction and heart failure, eplerenone: Reduced all-cause mortality, and reduced death or hospitalization due to cardiovascular events Had no effect on the incidence of gynecomastia Increased the incidence of serious hyperkalemia but decreased serious hypokalemia

More Related